[Cost-effectiveness of hypertension treatment in Catalonia (Spain)].

Autor:	Plans Rubió P; Servei d'Avaluació i Seguiment de Programes, Direcció General de Salut Pública, Departament de Sanitat, Barcelona, Spain., Tresserras Gaju R, Navas Alcalá E, Pardell Alentá H
Jazyk:	Spanish; Castilian
Zdroj:	Medicina clinica [Med Clin (Barc)] 2002 Feb 23; Vol. 118 (6), pp. 211-6.
DOI:	10.1016/s0025-7753(02)72338-5
Abstrakt:	Background: We assessed the cost-effectiveness of pharmacological treatments for hypertension to prevent coronary heart disease and stroke in Catalonia (Spain). Methods: Cost-effectiveness was measured as the cost in Spanish Ptas per life year gained (LYG) in 1998 in individuals aged 40 to 69 years with moderate/severe hypertension (>= 105 mmHg) and mild hypertension (95-104 mmHg). We evaluated hydrochlorothiazide (diuretic), propranolol (-blocker), nifedipine (calcium antagonist), captopril (angiotensin-converting-enzyme inhibitor) and prazosin (*-adrenergic blocker). Results: Cost-effectiveness ranged from 706,100 to 446,780 ptas. per LYG in men and from 635,100 to 810,270 ptas. per LYG in women with moderate/severe hypertension and from 108,770 to 682,460 ptas. per LYG in men and from 101,000 to 12,699,000 ptas. per LYG in women with mild hypertension. Incremental cost-effectiveness analysis showed that hydrochlorothiazide and propranolol were the most cost-effective treatments in individuals with moderate/severe hypertension while hydrochlorothiazide and nifedipine were most cost-effective in those with mild hypertension. Conclusion: In this study, greatest-to-lowest cost-effectiveness of assessed treatments was as follows: hydrochlorohiazide, propranolol, nifedipine, prazosin and captopril in moderate/severe hypertension and hydrochlorothiazide, nifedipine, propranolol, prazosin and captopril in mild hypertension.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu